A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Status:
RECRUITING
Trial end date:
2027-02-11
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in Chinese subjects with heart failure with ejection fraction retention/mild ejection fraction reduction (HFpEF/HFmrEF) combined with obesity (BMI28kg/). This study will enroll about 141 NYHA Class II-III HFpEF/HFmrEF subjects combined with obesity. Eligible participants will be randomly assigned to IBI362 4 mg, IBI362 6 mg, or placebo at a ratio of 1:1:1, randomized by concomitant atrial fibrillation during screening (history/screening ECG).
The trial period includes a 2-week screening period, a 52-week double-blind treatment period, and a 4-week safety follow-up period.